Company intelligence / Profile preview
Enedra Therapeutics
Cambridge, England, United Kingdomenedratx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Enedra Therapeutics has not yet reported clinical results. The company’s pipeline consists of preclinical programs targeting mechanisms that enable cancer cell evolution and heterogeneity, aiming to develop the first personalized medicines effective against highly heterogeneous tumors. Their approach leverages advanced computational biology, genomics, CRISPR/RNAi screening, and patient-specific biomarkers to identify novel therapeutic targets.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules (likely)precision medicinesplatform-driven target discovery using computational and genomic science
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Deep Science Ventures (founding/investment partner)Cancer Research Horizons (founding/investment partner)
Beyond the preview
Go deeper on Enedra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enedra Therapeutics.